ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and…
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or…
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage…
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
TAMPA, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR)…
TAMPA, Fla., Sept. 27, 2023 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR)…
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating…
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610…
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a…
Highlights: Cadence digital full flow includes key new technologies, including a high-accuracy and massively scalable…
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the…